Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Clofazimine-containing regimen for newly diagnosed multidrug-resistant tuberculosis
ChiCTR1800020391Phase 4Completed
- Sponsor
- Beijing Chest Hospital
- Start
- Dec 2012
- Modality
- Light/Condition-Responsive Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of clofazimine in multidrug-resistant tuberculosis (MDR-TB) (2 arms), sponsored by Beijing Chest Hospital. Primary endpoint: Sputum conversion rate at the end of treatment. Started Dec 2012; status: completed.
02
Drugs
clofazimine
03
Conditions
multidrug-resistant tuberculosis (MDR-TB)
Beyond the preview
Go deeper on ChiCTR1800020391.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800020391.